CMS and DOJ Signal a Tougher Enforcement Era: Key Regulatory Takeaways for 2026
Author
Umer Tanweer leads the Global Compliance & Analytics function at Vector Health Compliance. His expertise includes multi-country transparency reporting, cross-border value transfer disclosure, and the remediation of compliance systems and processes. At Vector Health, he oversees the design and deployment of advanced analytics frameworks for compliance monitoring, working across regulatory, data science, and operational teams to ensure integrity, scalability, and global alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
After years of relatively light-touch oversight, both CMS and the Department of Justice are building the infrastructure and legal authority to pursue transparency and aggregate spend violations far more aggressively. A proposed CMS rule would give the agency real enforcement teeth over Open Payments audits, while a sweeping DOJ reorganization has consolidated fraud enforcement under a single new division, backed by a record-setting 2026 takedown. Meanwhile, state disclosure laws continue to expand on top of the federal framework. Here is what life sciences compliance and transparency reporting teams need to know.
Historically, CMS has had the authority to audit Open Payments submissions but lacked a strong mechanism to compel manufacturers to actually produce the records requested during an audit. A proposed rule folded into CMS’s broader interoperability and prior authorization rulemaking would change that. Under the proposal, failing to provide complete, accurate records within 30 days of an audit request would itself be treated as a reportable failure, triggering civil monetary penalties. The comment period on the proposal closed in mid-June 2026, and industry observers expect a final rule to take effect as early as late 2026 or early 2027.
- Penalties would apply on a per-year, per-record basis, covering documents such as canceled checks, written agreements, and ledgers.
- Steeper penalties are proposed for a “knowing” failure to produce records.
- The effort mirrors a broader trend: CMS has been auditing select drug and device manufacturers under Open Payments since 2022, and its FAQ library has expanded to address audit-specific questions.
Practically, this means documentation readiness can no longer be treated as a year-end exercise. What actually trips companies up mid-audit is rarely a lack of records altogether — it’s records that are scattered across systems, inconsistently formatted, or missing a clear chain of custody. Building continuously defensible documentation, rather than reconstructing it after an audit request lands, is becoming the baseline expectation.
DOJ’s Enforcement Update: A Newly Centralized Fraud Apparatus
A genuine structural shift is underway inside the DOJ. On April 7, 2026, Acting Attorney General Todd Blanche announced the creation of the National Fraud Enforcement Division (NFED), a new stand-alone litigating division consolidating the Criminal Division’s Health Care Fraud Unit, its Tax Section, and its Market, Government, and Consumer Fraud Unit under one command structure. The initiative traces back to a White House announcement in January 2026 establishing a broader anti-fraud task force chaired by Vice President J.D. Vance, with FTC Chairman Andrew Ferguson as vice chair.
- Every U.S. Attorney’s Office has been directed to assign a dedicated prosecutor to the new division.
- DOJ’s grant-making components are standing up programs to let state and local prosecutors serve as Special Attorneys or Special Assistant U.S. Attorneys on federal fraud matters.
- The FBI is redirecting additional agents to support fraud investigations tied to the new division.
This consolidation matters for life sciences companies because it centralizes authority and data-sharing across previously siloed enforcement functions, which legal observers expect to translate into earlier investigative activity, more parallel civil and criminal proceedings, and closer coordination across cases — including matters that touch transfer-of-value reporting, Anti-Kickback Statute exposure, and Stark Law risk.
The Numbers Behind the Rhetoric: 2026’s National Health Care Fraud Takedown
The scale of this new enforcement posture became concrete in June 2026. The DOJ’s annual National Health Care Fraud Takedown, announced June 23-24, resulted in charges against 455 defendants, including 90 licensed medical professionals, in schemes the department valued at more than $6.5 billion in false claims. The action spanned 56 federal districts and included international arrests in Cyprus, Estonia, and the Philippines tied to multibillion-dollar schemes.
- Related actions included 1,079 CMS provider suspensions and 1,403 billing-privilege revocations.
- DOJ officials described a new data-sharing arrangement with CMS providing dedicated cloud computing capacity for real-time analytics, plus new information-sharing agreements with the FTC and Customs and Border Protection.
- A newly formed Financial Intelligence Review Team brought its first prosecution within seven months of identifying a suspect billing pattern — a signal of how quickly data-driven leads are now becoming cases.
For transparency and compliance teams, the operative lesson is that billing and reporting anomalies can attract scrutiny independent of any whistleblower complaint. Voluntary self-disclosure and demonstrably strong internal controls remain, by DOJ’s own account, the most effective way to reduce exposure.
State Disclosure Laws Are Compounding the Federal Picture
A patchwork of state requirements continues to add complexity on top of federal Open Payments obligations. Nearly 30 states and the District of Columbia now have enacted or pending laws touching pharma marketing restrictions, gift limitations, sales representative licensure, and expanded disclosure requirements.
- Roughly ten states, including Vermont, California, Colorado, New Jersey, and Massachusetts, restrict or prohibit certain gifts to HCPs, with similar measures pending in New York and Pennsylvania.
- An emerging trend requires local licensure or registration of pharmaceutical sales representatives who interact with HCPs, with Chicago cited as an early mover.
- States including New York, New Mexico, and New Jersey continue to expand disclosure granularity requirements beyond what federal Sunshine Act reporting already covers.
Because these state requirements often carry different deadlines, thresholds, and recipient definitions than the federal program, manual, spreadsheet-driven approaches to multi-jurisdiction reporting are becoming increasingly difficult to defend during an audit — federal or state.
What This Means for Transparency Reporting Teams
Taken together, these developments point to the same operational reality: audit-readiness, documentation integrity, and data governance are no longer back-office concerns — they are frontline risk management. Compliance teams should expect more frequent CMS audit requests, faster DOJ investigative timelines enabled by centralized data analytics, and a continuing expansion of state-level disclosure obligations layered on top of federal reporting.
Vector Health Solutions works with global life sciences compliance teams to build audit-ready transfer-of-value reporting programs — from centralized aggregate spend data and HCP identity matching to multi-jurisdiction reporting workflows that hold up under CMS and state-level scrutiny. If your team is evaluating how prepared your current reporting infrastructure is for this enforcement environment, we’re glad to talk through what we’re seeing across the industry.
After years of relatively light-touch oversight, both CMS and the Department of Justice are building the infrastructure and legal authority to pursue transparency and aggregate spend violations far more aggressively. A proposed CMS rule would give the agency real enforcement teeth over Open Payments audits, while a sweeping DOJ reorganization has consolidated fraud enforcement under a single new division, backed by a record-setting 2026 takedown. Meanwhile, state disclosure laws continue to expand on top of the federal framework. Here is what life sciences compliance and transparency reporting teams need to know.
Historically, CMS has had the authority to audit Open Payments submissions but lacked a strong mechanism to compel manufacturers to actually produce the records requested during an audit. A proposed rule folded into CMS’s broader interoperability and prior authorization rulemaking would change that. Under the proposal, failing to provide complete, accurate records within 30 days of an audit request would itself be treated as a reportable failure, triggering civil monetary penalties. The comment period on the proposal closed in mid-June 2026, and industry observers expect a final rule to take effect as early as late 2026 or early 2027.
- Penalties would apply on a per-year, per-record basis, covering documents such as canceled checks, written agreements, and ledgers.
- Steeper penalties are proposed for a “knowing” failure to produce records.
- The effort mirrors a broader trend: CMS has been auditing select drug and device manufacturers under Open Payments since 2022, and its FAQ library has expanded to address audit-specific questions.
Practically, this means documentation readiness can no longer be treated as a year-end exercise. What actually trips companies up mid-audit is rarely a lack of records altogether — it’s records that are scattered across systems, inconsistently formatted, or missing a clear chain of custody. Building continuously defensible documentation, rather than reconstructing it after an audit request lands, is becoming the baseline expectation.
DOJ’s Enforcement Update: A Newly Centralized Fraud Apparatus
A genuine structural shift is underway inside the DOJ. On April 7, 2026, Acting Attorney General Todd Blanche announced the creation of the National Fraud Enforcement Division (NFED), a new stand-alone litigating division consolidating the Criminal Division’s Health Care Fraud Unit, its Tax Section, and its Market, Government, and Consumer Fraud Unit under one command structure. The initiative traces back to a White House announcement in January 2026 establishing a broader anti-fraud task force chaired by Vice President J.D. Vance, with FTC Chairman Andrew Ferguson as vice chair.
- Every U.S. Attorney’s Office has been directed to assign a dedicated prosecutor to the new division.
- DOJ’s grant-making components are standing up programs to let state and local prosecutors serve as Special Attorneys or Special Assistant U.S. Attorneys on federal fraud matters.
- The FBI is redirecting additional agents to support fraud investigations tied to the new division.
This consolidation matters for life sciences companies because it centralizes authority and data-sharing across previously siloed enforcement functions, which legal observers expect to translate into earlier investigative activity, more parallel civil and criminal proceedings, and closer coordination across cases — including matters that touch transfer-of-value reporting, Anti-Kickback Statute exposure, and Stark Law risk.
The Numbers Behind the Rhetoric: 2026’s National Health Care Fraud Takedown
The scale of this new enforcement posture became concrete in June 2026. The DOJ’s annual National Health Care Fraud Takedown, announced June 23-24, resulted in charges against 455 defendants, including 90 licensed medical professionals, in schemes the department valued at more than $6.5 billion in false claims. The action spanned 56 federal districts and included international arrests in Cyprus, Estonia, and the Philippines tied to multibillion-dollar schemes.
- Related actions included 1,079 CMS provider suspensions and 1,403 billing-privilege revocations.
- DOJ officials described a new data-sharing arrangement with CMS providing dedicated cloud computing capacity for real-time analytics, plus new information-sharing agreements with the FTC and Customs and Border Protection.
- A newly formed Financial Intelligence Review Team brought its first prosecution within seven months of identifying a suspect billing pattern — a signal of how quickly data-driven leads are now becoming cases.
For transparency and compliance teams, the operative lesson is that billing and reporting anomalies can attract scrutiny independent of any whistleblower complaint. Voluntary self-disclosure and demonstrably strong internal controls remain, by DOJ’s own account, the most effective way to reduce exposure.
State Disclosure Laws Are Compounding the Federal Picture
A patchwork of state requirements continues to add complexity on top of federal Open Payments obligations. Nearly 30 states and the District of Columbia now have enacted or pending laws touching pharma marketing restrictions, gift limitations, sales representative licensure, and expanded disclosure requirements.
- Roughly ten states, including Vermont, California, Colorado, New Jersey, and Massachusetts, restrict or prohibit certain gifts to HCPs, with similar measures pending in New York and Pennsylvania.
- An emerging trend requires local licensure or registration of pharmaceutical sales representatives who interact with HCPs, with Chicago cited as an early mover.
- States including New York, New Mexico, and New Jersey continue to expand disclosure granularity requirements beyond what federal Sunshine Act reporting already covers.
Because these state requirements often carry different deadlines, thresholds, and recipient definitions than the federal program, manual, spreadsheet-driven approaches to multi-jurisdiction reporting are becoming increasingly difficult to defend during an audit — federal or state.
What This Means for Transparency Reporting Teams
Taken together, these developments point to the same operational reality: audit-readiness, documentation integrity, and data governance are no longer back-office concerns — they are frontline risk management. Compliance teams should expect more frequent CMS audit requests, faster DOJ investigative timelines enabled by centralized data analytics, and a continuing expansion of state-level disclosure obligations layered on top of federal reporting.
Vector Health Solutions works with global life sciences compliance teams to build audit-ready transfer-of-value reporting programs — from centralized aggregate spend data and HCP identity matching to multi-jurisdiction reporting workflows that hold up under CMS and state-level scrutiny. If your team is evaluating how prepared your current reporting infrastructure is for this enforcement environment, we’re glad to talk through what we’re seeing across the industry.
Author
Umer Tanweer leads the Global Compliance & Analytics function at Vector Health Compliance. His expertise includes multi-country transparency reporting, cross-border value transfer disclosure, and the remediation of compliance systems and processes. At Vector Health, he oversees the design and deployment of advanced analytics frameworks for compliance monitoring, working across regulatory, data science, and operational teams to ensure integrity, scalability, and global alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance